Catalyst Wire Dossier Catalyst Wire Dossier

Tanfanercept (HL036) ophthalmic solution

Tanfanercept · HanAll BioPharma Co., Ltd.
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for Tanfanercept (HL036) ophthalmic solution, covering 2023-10-23 to 2023-10-23. Get the full timeline:

Most recent: Clinical Trial Update: A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye [Phase 3]

See pricing